[Janus tacrolimus-eluting carbostent. Immediate and medium-term clinical results].
This observational and clinical follow-up study involved the first 50 patients who were treated with the Janus tacrolimus-eluting carbostent (Sorin Group) at our hospital. The patients' mean age was 66 (10) years, 38% were diabetic, and 56% were admitted with acute coronary syndrome. In total, 56 lesions were treated (52% were type B2/C), of which 12% involved in-stent restenosis, 5% were chronic occlusions, 23% were long lesions (>20 mm), 25% were in small vessels (< or = 2.5 mm), 7% were aorto-ostial lesions, 5% were in vein grafts, and 14% involved angiographically visible thrombus. Some 63 Janus carbostents were implanted (i.e., 1.26 [0.49] stents/patient). A successful outcome was achieved for all lesions. One patient (2%) required reintervention at the target lesion because of acute thrombosis. During a follow-up period of 10 (3) months, eight (16%) major adverse cardiac events occurred: there was one (2%) death due to heart failure and seven patients (14%) required revascularization, in five (10%) cases because of restenosis of the Janus carbostent.
García-Tejada
Julio
J
Servicio de Cardiología, Hospital 12 de Octubre, Madrid, Spain. juliogtejada@yahoo.com
Gutiérrez
Hipólito
H
Albarrán
Agustín
A
Hernández
Felipe
F
Velázquez
Teresa
T
Rodríguez
Sergio
S
Gómez
Iván
I
Tascón
Juan
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023903:Coronary Restenosis / Q000628:therapy; D023921:Coronary Stenosis / Q000628:therapy*; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents
D004343:Drug Implants; D007166:Immunosuppressive Agents; D020123:Sirolimus